High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma

References

• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Vose J M, Sharp G, Chan W C, Nichols C, Loh K, Inwards D, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20: 2344–2352
   PubMed Web of Science ®Google Scholar
• Sharp J G, Kessinger A, Mann S, Crouse D A, Armitage J O, Bierman P, et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214–219
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Beière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M G, Trümper L, Ma D, Österborg A, Pettengell R, Trneny M, et al. Randomized Intergroup Trial of First Line Treatment for Patients ≤60 years with Diffuse Large B-cell non-Hodgkin's Lymphoma (DLBCL) with a CHOP-Like Regimen with or without the anti-CD20 Antibody Rituximab-Early Stopping after the First Interim Analysis. Proc Am Soc Oncol 2004; 22(556), (abstract #6500)
   Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar
• Horwitz S M, Negrin R S, Blume K G, Breslin S, Stuart M G, Stockerl-Goldstein K E, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777–783
   PubMed Web of Science ®Google Scholar
• Khouri I, Saliba R, Hosing C, Okoroji G J, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240–2247
   PubMed Web of Science ®Google Scholar
• Gianni A M, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749–755
   PubMed Web of Science ®Google Scholar
• Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769–775
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Arcaini L, Bernasconi P, Alessandrino E P, Gargantini L, Cairoli R, et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229–235
   PubMed Web of Science ®Google Scholar
• Voso M T, Pantel G, Weis M, Schmidt P, Martin S, Moos M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729–735
   PubMed Web of Science ®Google Scholar
• Tothova E, Kafkova A, Guman T, Stecova N, Fricova M. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas. Neoplasma 2003; 50: 22–25
   PubMed Web of Science ®Google Scholar
• Belhadj K, Delfau-Larue M H, Elgnaoui T, Beaujean F, Beaumont J L, Pautas C, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol 2004; 15: 504–510
   PubMed Web of Science ®Google Scholar
• Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson J B, Nanji S, et al. Stem cell function and engraftment is not affected by “in vivo purging” with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26(5 Suppl 14)115–122
   PubMed Web of Science ®Google Scholar
• Hoerr A L, Gao F, Hidalgo J, Tiwari D, Blum K A, Mathews V, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561–4566
   PubMed Web of Science ®Google Scholar
• Endo T, Sato N, Mogi Y, Koizumi K, Nishio M, Fujimoto K, et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 703–707
   PubMed Web of Science ®Google Scholar
• Arcaini L, Orlandi E, Alessandrino E P, Iacona I, Brusamolino E, Bonfichi M, et al. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004; 34: 175–179
   PubMed Web of Science ®Google Scholar
• Donato M L, Champlin R E, Van Besien K W, Körbling M, Cabanillas F, Anderlini P, et al. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leukemia and Lymphoma 1999; 35: 317–324
   PubMed Web of Science ®Google Scholar
• StataCorp. Stata Statistical Software: Release 7.0. College Station. Stata Corporation, TX 2001
   Google Scholar
• Trotti A, Colevas A D, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181
   PubMed Web of Science ®Google Scholar
• Benekli M, Hahn T, Shafi F, Qureshi A, Alam A R, Czuczman M S, et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003; 32: 139–143
   PubMed Web of Science ®Google Scholar
• Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 921–923
   PubMed Web of Science ®Google Scholar
• Flinn I W, O'Donnell P V, Goodrich A, Vogelsang G, Abrams R, Noga S, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628–632
   PubMed Web of Science ®Google Scholar
• Hess G, Flohr T, Derigs H G. Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL. Ann Hematol 2002; 81(Suppl 2)S54–S55
   PubMed Web of Science ®Google Scholar
• Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869
   PubMed Web of Science ®Google Scholar
• Friedman J, Lazarus H M, Koc O N. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation. Bone Marrow Transplant 2000; 26: 831–836
   PubMed Web of Science ®Google Scholar
• Gribben J G, Neuberg D, Freedman A S, Gimmi C D, Pesek K W, Barber M, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–3457
   PubMed Web of Science ®Google Scholar